Search

Your search keyword '"Souto Maior AP"' showing total 13 results
Start Over Author "Souto Maior AP" Publication Year Range Last 50 years
13 results on '"Souto Maior AP"'

1. Favorable outcome of severe, extensive, granulocyte colony-stimulating factor-induced, corticosteroid-resistant Sweet's syndrome treated with high-dose intravenous immunoglobulin.

Author

Calixto R, Menezes Y, Ostronoff M, Sucupira A, Botelho LF, Florencio R, Martins M, and Souto Maior AP

Subjects
Adult, Biopsy, Humans, Male, Multiple Myeloma diagnosis, Remission Induction, Severity of Illness Index, Skin pathology, Sweet Syndrome chemically induced, Sweet Syndrome diagnosis, Treatment Outcome, Adrenal Cortex Hormones therapeutic use, Antineoplastic Agents adverse effects, Drug Resistance, Granulocyte Colony-Stimulating Factor adverse effects, Immunoglobulins, Intravenous therapeutic use, Multiple Myeloma drug therapy, Skin drug effects, Sweet Syndrome drug therapy
Published
2014
Full Text
View/download PDF

2. Coexistence of Leishmaniasis and Hodgkin's lymphoma in a lymph node.

Author

Domingues M, Menezes Y, Ostronoff F, Calixto R, Florencio R, Sucupira A, Souto-Maior AP, and Ostronoff M

Subjects
Adolescent, Animals, Hodgkin Disease complications, Humans, Leishmania donovani isolation & purification, Leishmaniasis, Visceral complications, Leishmaniasis, Visceral parasitology, Lymph Nodes parasitology, Male, Hodgkin Disease diagnosis, Leishmaniasis, Visceral diagnosis, Lymph Nodes pathology
Published
2009
Full Text
View/download PDF

3. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies.

Author

Ostronoff F, Ostronoff M, Souto-Maior AP, Domingues M, Sucupira A, Manso DA, de Lima AK, Monteiro PG, Florêncio R, and Calixto R

Subjects
Adolescent, Adult, Anemia, Aplastic blood, Anemia, Aplastic complications, Child, Drug Therapy, Combination, Female, Graft Rejection drug therapy, Graft Rejection immunology, Graft Survival drug effects, HLA Antigens metabolism, Humans, Kidney Function Tests, Male, Middle Aged, Mycophenolic Acid therapeutic use, Neutrophils cytology, Neutrophils immunology, Neutrophils metabolism, Prospective Studies, Risk Factors, Siblings, Survival Rate, Tissue Donors, Transplantation, Homologous, Treatment Outcome, Young Adult, Anemia, Aplastic therapy, Bone Marrow Transplantation, Cyclosporine therapeutic use, Graft vs Host Disease prevention & control, Granulocyte Colony-Stimulating Factor therapeutic use, Immunosuppressive Agents therapeutic use, Mycophenolic Acid analogs & derivatives
Abstract

The combination of methotrexate and cyclosporine A (MTX-CSA) is the standard regimen for the prevention of graft vs. host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-SCT) from HLA-identical siblings. Mycophenolate mofetil and CSA (MMF-CSA) combination has been successfully used for GVHD prophylaxis after non-reduced intensity conditioning (non-RIC) allo-SCT with peripheral blood or non-G-CSF stimulated bone marrow as stem cell source. We report the results of the first prospective trial of the MMF-CSA combination for acute GVHD prophylaxis in 47 patients after non-RIC G-CSF stimulated allo-BMT (G-BMT) from HLA-identical siblings in patients with severe aplastic anemia (SAA) or hematological malignancies. Median age was 28 yr (range, 6-48 yr). Median follow-up was 22 months. The median time to neutrophil and platelets recovery were nine d (range, 8-17) and 16 d (range, 10-28), respectively. Acute GVHD of grade II-IV and chronic GVHD occurred in 51% and 27%, respectively. Overall survival rates at two yr for patients with SAA and hematological malignancies were 87% and 65%, respectively. The event-free survival at two yr for patients with hematological malignancies was 76%. We concluded that MMF-CSA appears equivalent to MTX-CSA for GVHD prophylaxis in patients receiving non-RIC G-BMT from HLA-identical siblings, with a tendency for more rapid neutrophil engraftment.

Published
2009
Full Text
View/download PDF

4. Evidence for a graft-versus-leukemia effect in the central nervous system.

Author

Ostronoff F, Ostronoff M, Fernandes HS, Buessio R, Soriano S, Souto-Maior AP, Sucupira A, Domingues M, Florencio R, Tagliari C, and Calixto R

Subjects
Acute Disease, Hematopoietic Stem Cell Transplantation, Humans, Leukemia pathology, Recurrence, Transplantation, Homologous, Central Nervous System Neoplasms therapy, Graft vs Leukemia Effect, Leukemia therapy
Published
2008
Full Text
View/download PDF

5. Life-threatening hemolytic-uremic syndrome treated with rituximab in an allogeneic bone marrow transplant recipient.

Author

Ostronoff M, Ostronoff F, Calixto R, Florêncio R, Florêncio M, Domingues MC, Souto Maior AP, Sucupira A, and Tagliari C

Subjects
Adult, Antibodies, Monoclonal, Murine-Derived, Hemolytic-Uremic Syndrome physiopathology, Humans, Male, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Rituximab, Transplantation, Homologous, Antibodies, Monoclonal therapeutic use, Bone Marrow Transplantation adverse effects, Hemolytic-Uremic Syndrome etiology, Hemolytic-Uremic Syndrome therapy
Published
2007
Full Text
View/download PDF

6. Fludarabine, cyclophosphamide, and antithymocyte globulin for a patient with dyskeratosis congenita and severe bone marrow failure.

Author

Ostronoff F, Ostronoff M, Calixto R, Florêncio R, Domingues MC, Souto Maior AP, Sucupira A, and Tagliari C

Subjects
Antilymphocyte Serum therapeutic use, Bone Marrow Diseases complications, Bone Marrow Diseases drug therapy, Child, Preschool, Cyclophosphamide therapeutic use, Dyskeratosis Congenita complications, Female, Humans, Vidarabine analogs & derivatives, Vidarabine therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Dyskeratosis Congenita drug therapy
Published
2007
Full Text
View/download PDF

7. Pichia ohmeri fungemia in a hematologic patient: an emerging human pathogen.

Author

Ostronoff F, Ostronoff M, Calixto R, Domingues MC, Souto Maior AP, Sucupira A, Florêncio R, and Tagliari C

Subjects
Amphotericin B therapeutic use, Antifungal Agents therapeutic use, Female, Fungemia drug therapy, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Middle Aged, Mycoses drug therapy, Fungemia microbiology, Leukemia, Myelogenous, Chronic, BCR-ABL Positive microbiology, Mycoses microbiology, Pichia isolation & purification
Published
2006
Full Text
View/download PDF

8. Multidrug-resistant Pseudomonas aeruginosa infection in neutropenic patients successfully treated with a combination of polymyxin B and rifampin.

Author

Ostronoff M, Ostronoff F, Sucupira A, Souto Maior AP, Caniza M, Florêncio R, Domingues MC, Calixto R, and Matias K

Subjects
Adult, Cellulitis drug therapy, Cellulitis microbiology, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Neutropenia, Phlebitis drug therapy, Phlebitis microbiology, Pseudomonas Infections drug therapy, Pseudomonas Infections microbiology, Treatment Outcome, Anti-Bacterial Agents therapeutic use, Drug Resistance, Multiple, Bacterial, Polymyxin B therapeutic use, Pseudomonas aeruginosa drug effects, Rifampin therapeutic use
Published
2006
Full Text
View/download PDF

9. Reduced intensity conditioning allogeneic bone marrow transplantation following central nervous system (CNS) relapse of acute promyelocytic leukemia: evidence for a graft-versus-leukemia effect in the CNS.

Author

Ostronoff M, Domingues MC, Ostronoff F, Matias C, Florêncio R, Matias K, Souto Maior AP, Sucupira A, Calixto R, and Tagliari C

Subjects
Adult, Central Nervous System Neoplasms immunology, Humans, Male, Recurrence, Remission Induction, Transplantation, Homologous, Bone Marrow Transplantation, Central Nervous System Neoplasms etiology, Graft vs Leukemia Effect immunology, Leukemia, Promyelocytic, Acute surgery, Transplantation Conditioning methods
Published
2006
Full Text
View/download PDF

10. Safety of fractionated dose of rituximab in renal failure patients receiving hemodialysis.

Author

Ostronoff F, Ostronoff M, Florêncio R, Matias C, Souto Maior AP, Domingues MC, Calixto R, Sucupira A, Matias K, and Tagliari C

Subjects
Aged, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Fatal Outcome, Female, Humans, Lymphoma, Non-Hodgkin complications, Male, Middle Aged, Remission Induction, Rituximab, Venous Thrombosis complications, Antibodies, Monoclonal administration & dosage, Antineoplastic Agents administration & dosage, Lymphoma, Non-Hodgkin drug therapy, Renal Dialysis methods, Renal Insufficiency drug therapy
Published
2006

11. Hemophagocytic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma; successful treatment with high-dose intravenous immunoglobulin.

Author

Ostronoff M, Ostronoff F, Coutinho M, Calixto R, Souto Maior AP, Sucupira A, Florencio R, and Tagliari C

Subjects
Cytokines metabolism, Female, Humans, Immune System metabolism, Lymphohistiocytosis, Hemophagocytic diagnosis, Middle Aged, Phagocytosis, Time Factors, Treatment Outcome, Immunoglobulins, Intravenous therapeutic use, Lymphohistiocytosis, Hemophagocytic etiology, Multiple Myeloma complications, Multiple Myeloma therapy, Peripheral Blood Stem Cell Transplantation adverse effects, Transplantation, Autologous adverse effects
Published
2006
Full Text
View/download PDF

12. Allogeneic bone marrow transplantation in a child with severe aplastic anemia and hemophilia A.

Author

Ostronoff M, Ostronoff F, Campos G, Arruda S, Vaz C, Florencio R, Calixto R, Souto Maior AP, Sucupira A, Domingues M, and Tagliari C

Subjects
Anemia, Aplastic complications, Child, Child, Preschool, Factor VIII genetics, Fatal Outcome, Hemophilia A complications, Histocompatibility Testing, Humans, Male, Platelet Transfusion, Recurrence, Siblings, Transplantation Conditioning methods, Transplantation, Homologous, Anemia, Aplastic therapy, Bone Marrow Transplantation methods, Hemophilia A therapy
Published
2006
Full Text
View/download PDF

13. Serious thrombocytopenia due to dengue hemorrhagic fever treated with high dosages of immunoglobulin.

Author

Ostronoff M, Ostronoff F, Florêncio R, Florêncio M, Domingues MC, Calixto R, Sucupira A, Souto Maior AP, Matias C, Matias K, Tagliari C, and Soussain C

Subjects
Adult, Aged, Dengue Virus drug effects, Female, Humans, Middle Aged, Pregnancy, Severe Dengue complications, Severe Dengue mortality, Immunoglobulins therapeutic use, Severe Dengue drug therapy, Thrombocytopenia etiology
Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results